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Key causes of olfactory dysfunction 
include sinonasal disease, upper 
respiratory tract infection, post-viral 
olfactory loss (PVOL) or post-traumatic 
olfactory loss (PTOL), but its onset can 
sometimes mark neurodegenerative 
diseases, such as Parkinsonism, or 
point to underlying systemic disease, 
such as hypothyroidism. True gustatory 
dysfunction is rare. Although many 
patients complain of a ‘loss of taste’, this 
is actually due to their loss of retronasal 
olfaction, where 80% of the flavour of food 
is derived from its aroma.
what does olfactory loss mean to 
the sufferer?
‘When I lost my sense of smell it was 
like being struck blind. Life lost a good 
deal of its savour... My whole world was 
radically poorer.’ 
–  Excerpt from The Man Who Mistook 
His Wife For a Hat by O Sacks, as 
featured in Aroma.
An absent or poor sense of smell 
can cause wide-ranging problems for 
patients, including reduction in quality or 
enjoyment of life, leading to depression, 
feelings of social isolation, breakdown of 
relationships, threat of personal injury and 
potential loss of livelihood. Most patients 
with olfactory loss will complain about 
a loss of taste. Although true gustatory 
function is rarely impaired, sufferers will 
have a loss of flavour perception, which 
can adversely affect their appetite and this 
can be made even worse if distortions 
(such as parosmia) co-exist. 
Patients may well adopt poor dietary 
habits as a consequence, which may then 
have other impacts on their global health, 
as they will tend to eat a less varied diet. 
There are currently no estimates of the 
total burden or cost of anosmia to the UK 
as a whole, or the proportion of patients 
currently treated. In studies from other 
countries, three quarters of patients are 
reported to have experienced hazards 
due to their disorder, with half suffering 
depression.4-6 As well as decreased 
appreciation of food and suppression 
of appetite, other negative effects are 
seen on physical health, financial security, 
profession, partnership, friendship, 
emotional stability and leisure.7
history of the smell and taste clinic
In October 2010, a monthly clinic was 
established at the James Paget Hospital 
with a view to focusing referrals from 
the local catchment area into a specialist 
clinic where olfactory and/or gustatory 
testing could be performed. However, 
with increasing awareness of the clinic 
regionally and nationally, the clinic’s 
referral base grew and more than 75% 
of referrals now come from outside the 
immediate catchment area. This was 
accentuated when the anosmia patient 
support group, Fifth Sense, was founded 
and organised publicity for a fundraising 
event in Norwich, drawing heightened 
media attention. 
The clinic now runs at least twice a 
month, with a limit of six new and six 
follow-up patients over a three-hour 
period, allowing time for adequate 
consultation for each patient. Patients 
complete an Olfactory Disorders 
Proforma and Sino-Nasal Outcome 
Test-22 (SNOT-22) questionnaire 
on arrival. Prior to consultation, a 
olfactory dysfunction is common, 
affecting 1–5% of those under the age 
of 601 and at least 20% of those aged 
more than 60 years.2 in many UK 
centres, the approach to it is variable 
and routine olfactory testing is not 
performed, as noted by a recent 
survey of British ent surgeons.3 
this is in contrast to europe and the 
USa, where many specialist smell 
and taste centres already exist. 
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dedicated nurse performs a Sniffin’ 
Sticks® olfactory test (Heinrich 
Burghart GMBH, Germany). This 
test uses pen-like odour-dispensing 
devices to assess olfactory threshold, 
discrimination and identification (TDI), 
each scored to give an overall TDI 
score (specific to Sniffin’ Sticks), which 
ranks patients as anosmic, hyposmic or 
normosmic. The test has been validated 
for our local UK population,8 with TDI 
scores comparable to normative data 
published on large European samples.9,10 
Each replacement set costs £320 after 
an initial purchase of £700 and will last 
for 6 months (threshold) or 12 months 
(discrimination/identification) – this can 
be for any number of patients within 
this timeframe. 
current clinic data
Since October 2012, over 400 patients 
have visited the clinic. The average 
age was 57 (range 15 to 88 years). The 
female-to-male ratio was 1.5:1 (=105, 
=70). The most common aetiologies 
were chronic rhinosinusitis (CRS) with 
or without polyps (40%), idiopathic 
cases (30%) and PVOL (17%). Nineteen 
per cent had concurrent pathologies 
(more than one potential factor causing 
olfactory dysfunction) and three per 
cent had congenital anosmia (Figure 
1). Average scores for quantitative 
olfactory disorders varied according to 
diagnostic groups, thus patients with 
PVOL typically had a higher TDI score 
(me=18.48) compared with patients 
with idiopathic loss (me=13.82). There 
were gustatory disorders in 14 patients, 
with causes including idiopathic, post-
tonsillectomy and zinc-deficiency.
A common pathway for patients coming 
to the clinic has been used (Table 1). 
Qualitative disorders (eg distortions 
such as parosmia/phantosmia) usually 
occur in the presence of quantitative 
disorders, but not exclusively and are 
managed according to patient need 
(Table 2). Derived from the Olfactory 
Disorders Proforma, 20% of patients 
reported qualitative disturbances but 
only a minority felt this was more 
troublesome than their quantitative loss. 
Difficulties faced by the clinic
Owing to the pressures on nursing staff, 
the main difficulty is the provision of 
olfactory/gustatory testing. Unlike patients 
who come to clinic with hearing or visual 
disturbances, where there is a recognised 
tariff for the relevant test and staffing 
provided to facilitate this, there is no 
equivalent for smell or taste tests and this 
is not recognised by the National Institute 
for Health and Care Excellence (NICE) 
as the gold standard. Therefore follow-up 
tests have only been available for 10% of 
cases and so there is a need to collect 
further data on outcomes. Furthermore, 
there is always a financial concern 
regarding the clinic being maintained, 
owing to the costs of providing staff and 
test kits for this service and the lower 
capacity of such clinics. Submissions to 
NICE and NHS specialist commissioning 
are in progress but in the current financial 
climate, this service may not get the 
attention it needs to continue.
BOX AND wHISKER PLOT OF TDI SCORES GROUPED BY DIAGNOSIS
figUre 2
BAR CHART OF DIAGNOSES OF PATIENTS ATTENDING THE SMELL AND 
TASTE CLINIC
figUre 1
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what does the clinic offer that 
is new?
First and foremost, the clinic is there 
to allow patients to have a thorough 
assessment of their sensory disorder. 
Experience to date is that many patients 
have come to the clinic feeling isolated 
about their ‘invisible’ problem, which 
they feel has been neglected by medical 
professionals. Some patients have 
not progressed beyond primary care, 
whereas others have been seen in 
secondary care and perhaps received 
some investigations, but ultimately 
many have felt that their olfactory or 
gustatory loss has either not been fully 
explained or evaluated or they have 
not been counselled on the prognosis 
or consequences. As the subjective 
impression of olfactory function often 
correlates poorly with performance 
on psychophysical testing,11,12 formal 
olfactory assessment is therefore 
crucial alongside a thorough history 
and examination. Furthermore, this 
information aids prognosis, as patients 
with hyposmia are more likely to 
demonstrate potential for recovery 
in certain conditions than those with 
hyposmia (eg PVOL, PTOL). 
Endoscopic nasal examination is always 
performed to assess contributing 
pathology such as mucosal congestion, 
mucopus, polyps, neoplasms, anatomical 
anomalies and cerebrospinal fluid 
leaks. Images are captured using a 
voice-activated image capture device 
(D-scope). In cases where nasal 
endoscopy is negative and there are 
no obvious causative factors in the 
history, blood tests may elucidate 
underlying medical causes such as 
hypothyroidism, diabetes mellitus, 
autoimmune disorders, anaemia and 
syphilis and MRI scans will assess any 
intracranial pathology. For patients 
with troublesome dysgeusia, copper, 
magnesium and zinc levels are checked. 
Any previous imaging is reviewed 
carefully to look for any subtleties that 
may have been overlooked.
Treatments offered will vary on an 
individual basis but any patients with 
chronic rhinosinusitis will be managed 
according to the guidelines from 
European Position Paper and those 
more recently provided by ENT UK 
‘MANY PATIENTS HAVE COME TO THE 
CLINIC FEELING ISOLATED ABOUT 
THEIR “INVISIBLE” PROBLEM’
INITIAL MANAGEMENT PATHwAY FOR PATIENTS ATTENDING THE SPECIALIST OLFACTORY AND GUSTATORY 
DISORDERS CLINIC
taBle 1
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on rhinosinusitis and nasal polyps.13 In 
this respect, any patients who require 
surgical intervention have the option 
to undergo image-guided sinus surgery 
using the Medtronic Fusion system to 
map preoperative CT images during 
the procedure. For patients without a 
conductive cause, treatment options are 
much more limited, owing to paucity 
of randomised controlled trials that 
underpin them. If patients have been 
given a trial of oral corticosteroids 
then other pharmaceutical options 
are explored with patients on the 
understanding that they are unlicensed 
for this indication. Another focus 
of the clinic is therefore to lead on 
research into the benefits of new 
potential treatments and a double-
blinded randomised controlled trial on 
the benefit of sodium citrate spray in 
sensorineural olfactory loss is currently 
underway. Smell training, wherein patients 
actively sniff bottles containing clove, 
lemon, rose and eucalyptus odours 
twice daily for at least 12 weeks, is 
encouraged as this has been shown to 
have some benefit.14
Advice on safety measures, such 
as labelling to prevent spoilt food 
consumption, is given. Accentuating 
eating experiences with condiments, 
foods and recipes is extremely 
beneficial. Patients are also allowed to 
explore homeopathic therapies like 
ginkgo biloba. Counselling patients on 
their likely prognosis ensures realistic 
expectation about outcomes; based on 
the patient mix to date, approximately 
50% have the potential for recovery 
with treatment or spontaneously. 
Finally, patients are directed to the 
patient support group Fifth Sense, which 
has a website and newsletter.  
See: www.fifthsense.org.uk. 
conclusion
Disorders of olfaction and taste are 
often ignored and trivialised when in fact 
they result in extremely poor quality 
of life. Often these problems are not 
thoroughly investigated and managed in 
the general otolaryngology clinic without 
the necessary expertise, equipment 
and time. This dedicated service has 
been appreciated by the patients who 
have been seen to date but more work 
is needed to measure outcomes and 
develop new treatments. 
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